Recurrence in the remnant urothelium is observed in £ 8% of cases, depending on the type of urinary diversion, with higher rates of urethral recurrence in heterotopic diversions. Thus, the diagnosis of recurrence in the remnant urothelium is challenging. In our series, urinary cytology had a sensitivity and specificity of 75.0% and 98.8% for detecting urethral recurrence, respectively. Approximately 70% of urethral recurrence cases were detected by cytology alone before the patients developed clinical symptoms, thus influencing consecutive survival. Background: We evaluated the diagnostic accuracy of urinary cytology (UCy) for detecting recurrence in the remnant urothelium (RRU) after radical cystectomy (RC) for urothelial cancer. Patients and Methods: We conducted a 10-year retrospective analysis of a prospectively collected, single-center RC database comprising 177 patients who had undergone follow-up examinations at our department with ! 1 available postoperative UCy specimen. UCy specimens were classified using the Papanicolaou scheme. Results: In total, 957 cytology specimens were collected. Negative UCy results were noted in 927 (96.8%), atypical urothelial cells in 19 (2.0%), and suspicious/positive for malignancy in 11 (1.2%) cases. RRU was diagnosed in 16 patients (9.1%) during a mean follow-up period of 37 months (range, 1-118 months). The mean interval from RC to RRU was 34.7 months. Only 2 of 11 positive UCy specimens (18.2%) were falsely positive, for an overall sensitivity and specificity of 56.3% and 98.8% for predicting RRU, respectively. Urethral recurrence was diagnosed by UCy alone before the patients had developed symptoms in 8 of 12 cases (66.7%). Patients with clinical symptoms at the diagnosis of RRU had poorer cancer-specific survival rates than those of asymptomatic patients, although this trend was not statistically significant (P ¼ .496). Moreover, positive UCy findings were associated with significantly lower overall survival (P < .001) and cancer-specific survival (P ¼ .04) compared with negative UCy findings. Conclusion: Our results underline the predictive value of UCy in the surveillance of the remnant urothelium, with early detection of urethral recurrence before the development of clinical symptoms. 
Introduction
The urologic cancer burden has increased globally, with 2.1 million kidney, bladder, and prostate cancer cases occurring worldwide in 2013, a 2.5-fold increase since 1990. 1 Urothelial cancer of the bladder ranks as the ninth most frequently diagnosed cancer worldwide. 2 According to the European Association of Urology guidelines, radical cystectomy (RC) is currently the reference standard treatment of primary, localized muscle-invasive and recurrent, bacillus Calmette-Guérinerefractory, high-risk, and nonmuscle-invasive bladder cancer. 3 The incidence of urethral recurrence and recurrence in the upper urinary tract (UUT) after RC has been reported to be low, ranging from 4% to 8.1%
4-10 and 1.8% to 6%, 4, 6, 8 respectively. Most recurrences develop during the first 2 postoperative years. [5] [6] [7] Distant recurrence develops in about 50% of patients treated with RC.
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Despite platinum-based chemotherapy, the median survival ranges from 9 to 26 months. 12, 13 Therefore, a strict oncologic follow-up protocol after RC is of high importance for the early detection of recurrence, allowing for timely treatment with the aim of improving patient outcomes. 4 In general, extravesical tumor spread and lymph node-positive disease found at RC are the most important risk factors for local and distant recurrence. 11, 14 Thus, novel imaging methods for more accurate preoperative staging before RC are still needed. 15 Conflicting data have been reported concerning the association between various pathologic features and recurrence in the remnant urothelium (RRU). A number of risk factors have been reported for UUT recurrence, such as advanced pathologic tumor stage, carcinoma in situ, or distal ureteral and urethral involvement in cystectomy specimens. [14] [15] [16] [17] Moreover, the type of urinary diversion, involvement of the prostate and bladder neck, tumor multifocality, pathologic stage, and anterior vaginal wall infiltration in women appear to be associated with a greater risk of urethral recurrence. 7, 14, [17] [18] [19] [20] [21] The exact schedule for surveillance of the remnant urothelium after RC has been debated. To the best of our knowledge, no established or standardized guidelines exist for determining the correct schedule for surveillance. 5, 22 Follow-up strategies for the remnant urethra have ranged from observation alone to more invasive follow-up examinations, including urethral cytology and urethroscopy, according to the pathologic findings concerning the degree of prostatic involvement found at RC. 14, 22 Regular UUT imaging with urography enables the study of the upper tract oncologically and functionally; however, only 38% of UUT recurrences were detected by follow-up imaging investigations. 23 Despite routine surveillance, as many as 80% of UUT recurrences 21 and 44.7% of urethral recurrences 5 were detected after the patients had developed clinical symptoms. Moreover, symptomatic urethral recurrence has been associated with advanced urethral tumor stage, a poorer prognosis, and an increased risk of cancer-specific death compared with asymptomatic patients. 5, 24, 25 Thus, continued evaluation of the remnant urothelium after RC appears to be effective. 5, 26, 27 In general, urinary cytology (UCy) is a simple and noninvasive method for routine surveillance after RC, with the aim of early detection of noninvasive urothelial recurrence. 28 Urethral recurrence was diagnosed in more than one half of patients using UCy alone in the absence of clinical symptoms. 5, 29 Moreover, the first positive UCy finding could predict radiologically detectable urothelial recurrence a median of 2.1 years earlier. 30 However, the evaluation of UCy specimens and interpretation of the findings after RC and urinary diversion remain more challenging than for a normally voided UCy specimen for screening of urothelial carcinoma, because the potential rate of false-positive results with the former procedure is about 64.7%. 31 This fact can be explained by the presence of inflammatory, degenerated glandular epithelial cells, histiocytes, and necrotic cellular debris from bowel-derived urinary diversions. 28, 32 The conflicting data regarding the diagnostic accuracy of UCy are not surprising because most surveillance schedules have not been standardized, previous studies on the subject are scarce, and cytologic data are difficult to interpret in the presence of urinary diversion. 5, 22, 29, 31 Reviewing our 10-year cystectomy database, the aim of the present study was to determine whether routine cytologic examinations after RC have an effect on subsequent detection of RRU and whether its early detection by positive cytology findings in asymptomatic patients is advantageous in terms of the oncologic outcome.
Patients and Methods
The present trial was performed in accordance with the Declaration of Helsinki and its amendments. 33 A cystectomy database with prospectively collected data from a single referral center 15, 34 was reviewed retrospectively after approval from the local ethics committee (study nos. UN3532; 274/4.4, AN2015-0085, and 348/4.10). From January 2006 to December 2015, the medical records of patients with localized muscle-invasive bladder cancer or recurrent, high-risk nonmuscle-invasive bladder cancer, who had undergone RC with urinary diversion and extended bilateral pelvic lymphadenectomy, 35 were reviewed. Patients who had undergone cystectomy for benign disease or nonurothelial cancer were not enrolled. Thus, 177 patients who had undergone oncologic follow-up examinations at our outpatient department with ! 1 follow-up UCy were included in the present study. Follow-up investigations were performed every 3 months in the first postoperative year, every 6 months to the fifth year, and then once annually. In accordance with our institutional practice, each follow-up visit included complete laboratory examinations (blood gas analysis, prostate-specific antigen determination, and vitamin B 12 measurement from the fifth year onward), urinary analysis and cytology, measurement of residual urine in the orthotopic neobladder, and imaging studies (computed tomography scan every second visit or chest radiography combined with abdominal ultrasonography). RRU was diagnosed by positive cytology and/or positive radiologic imaging findings (with or without the appearance of related clinical symptoms, such as gross hematuria) and subsequently confirmed histologically by biopsy.
The cytologic specimens included voided urine, catheterized urine, and urethral washings. Urine cytologic analysis involved microscopic identification of exfoliated tumor cells. The classification scheme proposed by Papanicolaou includes 5 classes for reporting UCy. Classes 1 and 2 were essentially considered to indicate negative findings. Class 3 (atypical urothelial cells) indicated a suspicion of urothelial cancer, and classes 4 and 5 were considered suspicious and positive for malignancy, respectively. 
Urine Cytology and Urothelial Recurrence
In brief, exfoliated tumor cells obtained as a sediment after centrifugation (1000 rpm for 5 minutes) of a voided urine sample were fixed, stained using the Papanicolaou procedure, and reviewed by 2 urocytopathologists with long-standing experience. Representative stained cytologic slides are shown in Figure 1 .
The discriminatory power of UCy to predict RRU (overall, urethra, and UUT) was investigated by calculating the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), false positivity, false negativity, and 95% confidence intervals. UCy classes 1 to 3 were defined as negative and classes 4 and 5 as positive UCy results. Overall survival (OS) was calculated from the date of cystectomy to the date of death from any cause and cancer-specific survival (CSS) from the date of surgery or recurrence to the date of death from urothelial cancer. The patients were dichotomized into different groups (positive and negative cytology results and the presence and absence of symptoms) for KaplanMeier survival analysis and compared using the log-rank test. P .05 was considered statistically significant. The analyses and graphic diagrams were performed using GraphPad Prism, version 6 (GraphPad Software Inc, La Jolla, CA).
Results

Baseline Characteristics
A total of 177 patients (mean age, 68.3 years; range, 37-88 years) fulfilled the inclusion criteria and were included in the present study. An orthotopic ileal neobladder, an ileal conduit, a continent cutaneous catheterizable navel pouch, and ureterocutaneostomy were performed in 87 (49.2%), 86 (48.6%), 3 (1.6%), and 1 (0.6%) patient, respectively. In all 2460 lymph nodes (LNs) were removed and subjected to histologic investigation. The mean number of retrieved LNs per patient was 19.7 (range, 4-56). Histopathologic analysis confirmed 93 metastatic pelvic LNs (3.8%) in 23 of 177 patients (13.0%). The male-to-female ratio of the study population was 4.7:1 (146 men and 31 women). The mean interval between radical cystectomy and recurrence was 20 months (range, 3-117 months). During the mean follow-up period of 37 months (median, 33 months; range, 1-118 months), recurrent disease was detected in 48 patients (27.1%). Of these patients, 16 (9.1%) had developed RRU (urethra, n ¼ 12; UUT, n ¼ 4), 12 (6.8%), pelvic recurrence, and 20 (11.3%), distant metastasis. Tumor recurrence was confirmed by histologic examination of biopsy specimens in all patients. The descriptive and histopathologic characteristics of all patients are summarized in Table 1 .
Diagnostic Accuracy of UCy for RRU
A total of 957 UCy specimens from 177 patients were collected during follow-up after radical cystectomy. The findings were negative in 927 cases (96.8%), atypical urothelial cells were found in 19 (2.0%), a suspicion of malignancy was found in 8 (0.9%), and positive malignancy was found in 3 (0.3%). The mean number of UCy procedures per patient was 5.1 (median, 5.0; range, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Positive cytologic findings were confirmed in 11 of 177 patients (6.2%). Regarding the detection of recurrence in the remnant urothelium (urethra and UUT), the overall sensitivity, specificity, PPV, and NPV of UCy were 56.3%, 98.8%, 81.8%, and 95.8%, respectively ( Figure 2A ). The clinical, histopathologic, and therapy characteristics of the 16 patients with RRU are summarized in Table 2 .
Of the 12 patients with urethral recurrence, a positive cytology finding was noted in 9 (75%). The mean interval from RC to the detection of urethral recurrence was 24 months (median, 25 months; range, 4-45 months). Of these 12 patients, 8 (66.6%) had died after a mean follow-up period of 28.6 months (range, 7-48 months). No significant differences were found between the rate of urethral recurrence and the type of urinary diversion. However, a heterotopic urinary diversion was associated with a greater rate of urethral recurrence (8.1% for cutaneous diversion vs. 5.7% for orthotopic bladder substitution). In the 3 patients with false-negative cytology findings, the urethral recurrence was diagnosed by gross hematuria and the findings from subsequent invasive diagnostic procedures. In contrast, urethral recurrence was detected by UCy before the appearance of symptoms in 8 of the 12 patients (66.7%). The mean interval between surgery and the primary detection of urethral recurrence was 21.5 months for the symptomatic patients and 25.3 months for those without symptoms. The 2 patients with 1 false-positive cytology specimen per patient were closely monitored during the follow-up period. One patient remained recurrence free after 111 months of followup and had negative findings for the subsequent 9 UCy procedures. The second patient developed distant recurrent disease with liver and bone metastases 5 months after surgery and died 9 
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Clinical Genitourinary Cancer October 2017 -e787 months postoperatively. Accordingly, the calculated sensitivity, specificity, PPV, and NPV for UCy in detecting urethral recurrence were 75.0%, 98.8%, 81.8%, and 98.2%, respectively ( Figure 2B ). Of the 4 patients with UUT recurrence (2.3%), the recurrence was not detected by positive UCy findings in any patient. In contrast, UUT recurrence was diagnosed by positive radiologic imaging findings in 2 patients and by the presence of gross hematuria in 2 patients. The mean interval between surgery and UUT recurrence was 66.8 months (range, 3-117 months). One of these patients died of tumor progression after a mean follow-up period of 114.3 months (range, 62-234 months). The sensitivity, specificity, PPV, and NPV of UCy in detecting UUT recurrence were 0%, 93.7%, 0%, and 97.6%, respectively ( Figure 2C ).
Influence of UCy Findings and Clinical Symptoms on OS and CSS
Finally, we analyzed the differences in OS and CSS, stratified by UCy status and then by the presence or absence of symptoms. The Kaplan-Meier survival probability stratified by positive UCy findings is shown in Figure 2D ,E. Positive cytology findings were associated with significantly decreased OS (median, 42 vs. 117 months; P < .001) and CSS (median, 45 months vs. not estimated; P ¼ .04) compared with negative cytology findings.
The rate of CSS after urothelial recurrence did not differ significantly when stratified by the presence of clinical symptoms at the diagnosis of RRU. However, patients with symptoms had poorer CSS than that of asymptomatic patients (median, 4 vs. 16 months), although this trend was not statistically significant (P ¼ .496; Figure 2F ).
Discussion
We have presented a large UCy series of patients who underwent routine surveillance after RC. Nearly 1000 UCy specimens were collected at the same intervals. The incidence of urethral (6.8%) and UUT (2.3%) recurrence after RC was consistent with previous findings. [4] [5] [6] [7] [8] [9] [10] 16, 19, 31 We observed a statistical trend toward a lower rate of urethral recurrence after orthotopic reconstruction than after cutaneous diversion (5.7% vs. 8.1%). 5, 7, 24, 29 The correct protocol and timing of surveillance after RC continue to be debated, with conflicting evidence reported. 37, 38 A variety of schedules based on the choice of imaging method and intensity of the follow-up regimen have been proposed. 5, 26 Sherwood and Sagalowsky 22 suggested a surveillance algorithm using histopathologic risk factors such as prostatic involvement in RC specimens, a known independent predictor of urethral recurrence. 24 In confirmation, > 70% of men with urethral recurrence had prostatic involvement at RC in our series. The critical questions include whether routine follow-up examinations after RC are advantageous in terms of patient-related outcomes and whether the early diagnosis of urothelial recurrence by UCy is beneficial for subsequent patient survival, because it allows for conservative therapy before the development of invasive cancer and, thus, prevents disease progression. 26, 39 In the largest series of urethral recurrence after RC reported by Boorjian et al, 5 55% of cases were diagnosed by UCy before the patients had developed symptoms. In a follow-up investigation of 479 patients after RC, Giannarini et al 26 confirmed urethral recurrence in 88% using UCy. These data are comparable with the results from our series. Of our patients with urethral recurrence, 66.7% were asymptomatic and the recurrence was detected by positive UCy findings. Moreover, the symptomatic presentation of urethral recurrence was associated with advanced tumor stage at urethrectomy and poorer CSS and a poorer prognosis after recurrence compared with asymptomatic patients. 5, 6, [24] [25] [26] Of the patients with pelvic recurrence after RC, the median OS was also lower for those with symptomatic presentation compared with diagnosis by computed tomography (10.6 vs. 21.6 months). 40 When stratified by the presence of clinical symptoms, we found that symptomatic patients had poorer survival than asymptomatic patients whose recurrence was diagnosed by UCy (median CSS after recurrence, 4 vs. 16 months), although this trend did not achieve statistical significance (P ¼ .496).
In contrast, Lin et al 41 compared the survival of a series of 24 patients who underwent urethrectomy after RC detected by cytology (n ¼ 17) versus RC detected by symptoms such as gross hematuria (n ¼ 7). They found no significant differences between the 2 groups. 41 Furthermore, when the patients were compared on the basis of different surveillance schedules, no statistically significant difference was noted in the progression rates between those monitored and not monitored using regular urethral wash cytology. Although the rate of urethrectomy was slightly greater in patients monitored with cytology (20.8%) than without cytology (12.5%), no statistically significant association with tumor stage or disease progression was noted between the 2 groups (with and without cytology). 39 However, positive cytology findings were predictive of a greater likelihood of disease progression 39 and UUT recurrence 30 compared with those with negative cytologic findings, thus justifying a more intensive follow-up protocol. UCy has been recommended for monitoring the development of recurrence after RC. 28, 29, 35, 37, 42, 43 The exact procedure of urethral wash cytology was described by Varol et al, 29 using urethral barbotage washing for cytologic screening of urethral recurrence after RC. Monitoring patients with urinary diversion using a combination of cytologic analysis and quantitative digital cytometry was proposed by Caraway et al. 44 However, other investigators have argued against routine UCy because of its unconfirmed reliability, interpretation problems owing to cell degeneration, the rounding of small epithelial cells, and the high rates of falsepositive findings. 22, 31, 32, 38 In our series, the overall sensitivity and specificity of cytologic surveillance for RRU was 56.3% and 98.8%, respectively, consistent with previous findings.
31,37
However, we observed a much lower rate of false-positive results (1.2%) than in other series, 22, 31, 38 which have reported rates as high as 65%. 31 An explanation of the low false-positive rate might be the expertise and experience of the cytopathologists at our institution. Regarding urethral recurrence, we noted the greatest sensitivity (75%) for UCy. Of 9 patients with positive cytology findings, the recurrence was detected in 8 before they developed clinical symptoms. Regarding the critical question of whether urethral recurrence can be diagnosed earlier by cytology than by clinical symptoms, other series have confirmed our results: the urethral recurrence in 55% to 88% of patients was diagnosed by cytology alone before the patients became symptomatic, and a
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Clinical Genitourinary Cancer October 2017 -e789 significant effect on survival was noted after the diagnosis of recurrence. 5, 26 Our series included only 4 cases of UUT recurrence; however, none were detected primarily by UCy. The diagnostic accuracy of UCy in detecting UUT recurrence appears to be lower, because UUT recurrence was diagnosed by cytology rather than radiologic investigation in only 5.9% 31 and by clinical symptoms in as many as 80%. 21 Our study had some limitations. First, ours was a nonrandomized single-center observational study with a small number of urothelial recurrences (n ¼ 16) and retrospective study design. Thus, the present data strongly limit the quality and reproducibility for statistical interpretation and might reflect a certain selection bias owing to the exclusion of patients who were followed up elsewhere. However, we analyzed the data from a homogeneous patient population using a standardized surveillance protocol, collected cytology specimens at the same interval (4 times the first year, every 6 months until the end of the fifth year, and annually thereafter). Owing to the low incidence of RRU, prospective and multi-institutional randomized trials with larger numbers of patients and standardized follow-up intervals (with or without UCy) would be helpful to gain further knowledge regarding the most effective follow-up strategy for detecting RRU and the optimal duration of surveillance after RC.
Conclusion
Positive UCy findings had a sensitivity, specificity, PPV, and NPV of 75.0%, 98.8%, 81.8%, and 98.2%, respectively, for detecting urethral recurrence, with a low rate of false-positive findings. Urethral recurrence was detected by UCy in approximately 70% of patients before they developed clinical symptoms, thus influencing survival after recurrence. Therefore, we believe that UCy should be a part of the oncologic surveillance protocol for early detection of RRU after RC.
Clinical Practice Points
Oncologic surveillance after RC for bladder cancer is essential, because approximately 50% of these patients will develop local recurrence or distant metastasis. RRU is observed in 8% of patients, depending on the type of urinary diversion, with greater rates of urethral recurrence in those with heterotopic diversion. The diagnosis of RRU is challenging; UCy has been recommended for monitoring patients after RC in various studies. In our series, UCy had a confirmed sensitivity and specificity of 75.0% and 98.8% for detecting urethral recurrence; urethral recurrence was detected by UCy alone in approximately 70% of patients before they developed clinical symptoms, thus influencing consecutive survival.
